| Title | Palliation therapy for painful skeletal metastasis with Sm-153 | |
| Authors | Athanasios Zisimopoulos1, Dimitrios Psyllas1, Fotoula Babatsikou2, Grigorios Kyriatzis3, Evangelos Karathanos1 and Charilaos Koutis2
1. Department of Nuclear Medicine, University General Hospital of Alexandroupolis Medical School, Democritus University, Alexandroupolis, Greece 2. Laboratory of Epidemiology, Technological Educational Institution of Athens (TEI),Athens, Greece 3. Unit of Molecular biology, Democritus University, Molecular Biology and Genetics, Alexandroupoli, Greece |
|
| Citation | Zisimopoulos, A., Psyllas, D., Babatsikou, F., Kyriatzis, G., Karathanos, E. et al.: Palliation therapy for painful skeletal metastasis with Sm-153, Epitheorese Klin. Farmakol. Farmakokinet. 23(2): 85-88 (2009) | |
| Publication Date | Accepted for publication (Final Version): July 1, 2009 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Sm-153, Palliation therapy, skeletal metastasis, breast cancer, prostate cancer. | |
| Other Terms | review article | |
| Summary | Carcinoma of the breast is the most common cancer affecting women over the age of 40 years. And carcinoma of the prostate is the second most common carcinoma in men. Both commonly metastasize to bone and often present with multiple bone metastases as the primary clinical problem. Several treatment approaches have been tried for metastatic carcinoma with multiple skeletal metastases. 153Sm-EDTMP is a very good palliative performing radiopharmaceutical for painful skeletal metastases. It emits therapeutic medium – energy particles and gamma rays useful for gamma camera imaging. It has excellent pharmacokinetics with bone lesion uptake of up to 65% of the injected dose in the first couple of hours while up to 90% of the activity will be eliminated form the blood in the first half hour. The treatment appears to offer significant pain palliation with minimal myelotoxicity, preserving the quality of life of patients with multiple skeletal metastases. | |
| References | 1. Serafini N.A.: Therapy of metastatic bone pain. J. Nucl. Med. 42: 895-906 (2001)
2. Russ Knapp F.F., Mirzadeh Jr. S., Beets A.L., O’Doherty M., Blower P.J., Verdera E.S., Gaudiano J.S., Kropp J., Guhlke J., Palmedo H. Biersack H.J.: Reactor-produced radioisotopes from ORNL for bone pain palliation. Appl. Radiat. Isot. 49: 309-315 (1998) 3. Coronado M., Redondo A., Coya J., Espinosa E., Couto R.M., Zamora P., Marin M., Castelo B., Lillo M., Frutos L., Gonzalez B.M., Martin C., Luis M.: Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease. Clin. Nucl. Med. 31: 605-610 (2006) 4. Serafini N.A.: Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Am. Cancer Soc. 88 (S12): 2934-2939 (2008) 5. Goeckeler W.F., Edwards B., Volkert W.A., Holmes R.A., Simon J., Wilson D.: Skeletal localization of samarium-153chelates: Potential therapeutic bone agents. J. Nucl. Med. 28: 495-504 (1987) 6. Moro L., Fantinato D., Frigerio F., Shamhan G., Angelovski G.: Europium-154 contamination levels in Samarium-153-EDTMP for radionuclide therapy. J. Physics: Conference Series 41: 535–537 (2006) 7. Eat F.J., Collins C., Stabin M., Vernon C., Petersdorf S., Baker M., Hartnett S., Ferency S., Addison J.S., Appelbaum F., Gordon E.E.: Samarium-153-EDTMP biodistribution and dosimetry estimation. J. Nucl. Med. 34: 1031-1036 (1993) 8. Anderson M.P., Wiseman A.G., Dispenzieri A., Arndt A.S.C., Hartmann C.L., Smithson A. W., Mullan P.B., Bruland S.O.: High-dose Samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J. Clin. Oncol. 20: 189-196 (2002) 9. Tripathi M., Singhal T., Chandrasekhar N., Kumar P., Bal C., Jhulka P.K., Bandopadhyaya G., Malhotra A.: Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases. Indian J. Cancer 43: 86-92 (2006) 10. Singh A., Holmes A. R., Farhangi M., Volkert A. W., Williams A., Stringham M. L., Ketring R. A.: Human pharmacokinetics of Samarium-153 EDTMP in metastatic cancer. J. Nucl. Med. 30: 1814-1818 (1989) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2009 – ANNUAL SUBSCRIPTION 2009 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|